Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14076129 | 0.90 | NPC1 (0.58) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5275732 | 0.84 | NPC1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5696427 | 0.81 | HCAR2 (0.78) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL14112021 | 0.80 | KDM4E (0.77) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL10693261 | 0.79 | NPC1 (0.66) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5696463 | 0.77 | ALDH1A1 (0.85) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL5270832 | 0.76 | SUCNR1 (0.56) | CYP2C9SUCNR1LMNATSHRGAA | |
| SCHEMBL11517893 | 0.76 | ADRA2C (0.54) | CYP2C9ALDH1A1SUCNR1 | |
| SCHEMBL14112034 | 0.75 | KDM4E (0.66) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL20838832 | 0.75 | MAPK1 (0.72) | NPC1RAB9AMAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214638-A1 | Anthranilic Acid Derivatives Active as the Hm74a Receptor | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| US-20080214638-A1 | Anthranilic Acid Derivatives Active as the Hm74a Receptor | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214638-A1 | Anthranilic Acid Derivatives Active as the Hm74a Receptor | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214638-A1 | Anthranilic Acid Derivatives Active as the Hm74a Receptor | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1853555-A1 | ANTHRANILIC ACID DERIVATIVES ACTIVE AT THE HM74A RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006085111-A1 | ANTHRANILIC ACID DERIVATIVES ACTIVE AT THE HM74A RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214638-A1 | Anthranilic Acid Derivatives Active as the Hm74a Receptor | ANTXR2, HCAR1, GPR88 | NPC1 4180/4885RAB9A 504/4885MAPT 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.